Imatinib mesylate, used for the treatment of chronic myelogenous leukemia (CML), blocks both profibrotic TGF-β1 signaling and suppresses activity of the PDGF receptor [254, 255]. The gene discussed is TGFB1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.